Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
wow.. they finally going to nasdaq.. way overdue.. been holding for like 7 years now.. well who says buy and hold strategy is dead..
congrats worthylion and everyone else who have the vision to buy awrcf..
well.. we hit $5 today..
worthy,
what website do you use to check the price of these majority/minority holdings of AWRCF?
Also I wonder what is PEWC current structure? Are they publicly traded copmany? how many % of PEWC business is AWRCF?
Thanks,
Stan
wow friday night after hours went as high as 18% up.. nice volume too.. that is exciting.. will be interesting monday morning.. if there is any profit taking as it goes up or not.. hope the market is up too. can use some catalyst..
realfast95, thanks for the info.
who is Louis Navellier (or how's his track record) by the way. Is he an Analyst following MDF for a while.
in any case it's good news.
I'm holding mine for the long haul (till the day they started paying dividend)
Stan
------------------------------
MDF - Louis Navellier picked them for the Quantum Growth Friday evening.
Buy up to $5, target $9
thanks swampboots.. i think i might hold till the end of the year and the move on (and take the tax loss). I think it's jard to trust management ever if they let the price drop to these levels (I wouldn't do that if I'm management). anyway I'll pass on the chance that thsi could go to $2 again if end of year they didn't even post an update. totally irresponsible. being public company they should be obligated to at least post a pr on how the company is doing
so you still holding? when are you going to sell?
does this company still exist? do they have a website? are they going to say anything again ever? the stock is pretty much worthless. another pump and dump scheme I guess.
any thoughts on AYSI? any holders out there? after the voluntary deregistering the stock, any reason to continue holding the stock?
any thoughts on AYSI? any holders out there? after the voluntary deregistering the stock, any reason to continue holding the stock?
looks like this is a scam.. sad..
still strong.. oer $15 now.. thinking to sell some but getting greedy since no additional insider been selling recently..
$8, not too shabby. I was at walmart and see tilapia frozen meal (not from HQS) and they are quite pricey as well. just like HQS product so makes me feel good knowing that it is not just HQS product price is too high that no one probably want to buy
I hope you are right. I'm hopeful that HQS will be valued correctly in the future. nice move today with decent volume
ssk. np. i was more concerned that if my picks are not good to go then I'm not entered at all. I'm good either way (as long as I'm entered, whichever stocks is included in my picks, I'm good)
and yes, the trades are there for us to rearrange the picks when needed
ssk. thanks for putting my list in.
not sure if all of them qualified. if yrcw doesn't qualify, can you replace it with one of my backups. thanks.
Thanks Ronnie.. I'll do that. btw, I'm already investor. long term investor actually (used to be this board moderator 2 years ago). been in since the pre split.. most of my shares were bought at .26-.30 but that's pre 1 for 20 reverse split so I'm down right now. I'm wondering if I should average down.
If the stock drift to $2 next year and they still sell additional shares at $2 (with the additional warrant at $2.8 maybe) then I don't know what to say. if history repeats itself they will do that .. let's just hope the stock price will be higher than today the next time they decide to raise more money
Stan
14M shares for $79M raised so far ($5+) now at $3 (a bargain?)
Is that mean that the stock is such a bargain since most of the remaining shares were issued at $5+ in average?
Why would they issue shares at $3.6. And why is the stock at $3.1 now, especially since they have $2.6 in cash per share with no debt?
Are people thinking that HQS is merely a fraud and their primary business is to continue issuing more shares (but won't the new investor who will buy the new shares would do their DD)?
the sad part if PPS not improve the offering price might be adjusted lower..
I've seen that happen before and in this case for example the buyer will not want to buy at 3.6 because they said they can buy it from the market at 3.1 so they might ask to buy the shares at 3.1 instead and I'm sure if that happens HQS will gladly do so (if they are crazy enough to sell more shares at $3.6 , i'm sure they will take $3.1)
Still long but wonder if I should add more (doesn't make sense to sell though)
JMHO
Stan
Analyst are clueless on AOB and AOB management also doesn't seem to care much to correct. EPS won't improve till Q4 2010 IMO.. plenty of time for us to accumulate.. I like the long term prospect of AOB..
AOB Reports Second Quarter 2010 Financial Results
- Prescription and New Product Sales Ramp Up -
- Initial Success of R&D and Rural Area Focus Strategy Realized -
Press Release Source: American Oriental Bioengineering, Inc. On Monday August 9, 2010, 6:00 am EDT
NEW YORK, Aug. 9 /PRNewswire-Asia-FirstCall/ -- American Oriental Bioengineering, Inc. (NYSE:AOB - News), ("the Company" or "AOBO"), a pharmaceutical company dedicated to improving health through the development, manufacture and commercialization of a broad range of prescription and over the counter ("OTC") products, today announced financial results for the second quarter ended June 30, 2010.
Second Quarter 2010 Financial Performance
Revenue in the second quarter of 2010 increased 8.5% year over year to $77.3 million from $71.2 million, reflecting continued demand for the Company's core prescription products.
-- Revenue from pharmaceutical products increased 9.1% to $63.8 million from $58.4 million in the second quarter of 2009. Revenue from prescription pharmaceutical products increased 20.8% to $30.4 million from $25.2 million in the prior year period, primarily due to the increase sales of the Jinji capsule, SHL powder, YYQH capsule and the expansion of CCXA generic pharmaceutical products in the rural market. The overall increase in sales was supported by our continuous marketing efforts, increase in new products offerings, as well as expanding coverage in the rural market. OTC pharmaceutical products generated $33.4 million in revenue during the second quarter of 2010, compared to $33.3 million in the prior year period. -- Nutraceutical products generated revenue of approximately $9.9 million in the second quarter of 2010, up 4.3% from $9.5 million in the prior year period, reflecting increased sales of soybean milk as the market expanded. -- The Company generated $3.6 million from its distribution business, Nuo Hua, in the second quarter of 2010. An increase of 10.0% was mainly attributed to Nuo Hua's expanding market coverage.
Gross profit in the second quarter of 2010 was $39.8 million, compared to $41.6 million in the second quarter of 2009. Gross margin was 51.5%, compared to 58.4% in the prior year period and 52.5% in the prior quarter reflecting a greater proportion of generic product sales in the rural market. Further, the increased purchase prices of certain raw materials increased the cost of sales also contributed to lower gross profit.
Operating income in the second quarter of 2010 was $9.1 million, compared to $18.0 million in the prior year period. Selling and marketing expenses increased 22.4% to $11.5 million from $9.4 million in the prior year period, and advertising expense increased 18.5% to $9.2 million in the second quarter of 2010 from $7.8 million in the prior year period. General and administrative expenses increased 28.1% to $5.2 million from $4.0 million in the prior year period. Research and development expenses increased to $3.3 million from $0.8 million in the prior year period, reflecting the Company's continued efforts in research and development activities. Our research and development activities consist of near term, middle team and long term stages which contribute to both our current and future business strategies.
Net income attributable to controlling interest for the second quarter of 2010 was $5.1 million, compared to $12.6 million in the prior year period. The Company's net income attributable to controlling interest was $0.07 per diluted share, compared to $0.16 per diluted share in the same period of 2009.
Six Month Financial Performance
Revenue for the six months ended June 30, 2010 increased 11.7% to $131.0 million from $117.3 million in the first six months of 2009. During the same time period, gross profit was $68.1 million, compared to $70.0 million in the first six months of 2009. Operating income in the first six months of 2010 was $15.5 million, compared to $28.9 million in the first six months of 2009. Net income attributable to controlling interest for the first six months of 2010 was $8.2 million, compared to $19.7 million in the prior year period. In the first six months of 2010, net income per diluted share was approximately $0.11.
Balance Sheet
As of June 30, 2010, the Company had $96.4 million in cash and cash equivalents, and generated approximately $7.7 million of operating cash flow during the first half of 2010. Working capital was $147.0 million as of June 30, 2010, reflecting an increase of 12.3% from $130.9 million as of December 31, 2009.
Mr. Tony Liu, Chairman and Chief Executive Officer of American Oriental Bioengineering, commented, "AOBO's prescription product division ramped up very quickly in the second quarter of 2010. The double digit growth is a result of our previous investment in new products as well as continued strong demand for existing branded products. During the past quarter, we continued to execute our R&D-driven strategy, which consumed 4.2% of total revenue. Our focus on upgrading existing products and developing new ones will proactively prepare AOB for both near term and long term growth. Furthermore, we continued to strengthen and integrate AOBO's unified mega brand through an effective advertising campaign as well as fortify our presence in rural areas with advanced sales network expansion. Meanwhile, we consistently monitored our inventory of raw materials and assiduously controlled costs, which partially offset the two prevalent influences of rising raw material costs and labor costs. These combined efforts are aimed to help AOBO more effectively adjust to policy changes and capitalize on emerging opportunities."
Conference Call
The Company will hold a conference call at 8:00 am ET on Monday, August 9, to discuss its results. Listeners may access the call by dialing 1-800-573- 4842 or 1-617-224-4327 for international callers, access code: 10613898. A webcast will also be available through AOB's website at http://www.bioaobo.com . A replay of the call will be available through August 16, 2010. Listeners may access the replay by dialing 1-888-286-8010 or 1-617-801-6888 for international callers, access code: 35043398.
About American Oriental Bioengineering, Inc.
American Oriental Bioengineering, Inc. is a pharmaceutical company dedicated to improving health through the development, manufacture and commercialization of a broad range of prescription and over the counter products.
Safe Harbor Statement
Statements made in this press release are forward-looking and are made pursuant to the safe harbor provisions of the Securities Litigation Reform Act of 1995. Such statements involve risks and uncertainties that may cause actual results to differ materially from those set forth in these statements. The economic, competitive, governmental, technological and other factors identified in the Company's filings with the Securities and Exchange Commission, may cause actual results or events to differ materially from those described in the forward looking statements in this press release. The Company undertakes no obligation to publicly update or revise any forward- looking statements, whether because of new information, future events, or otherwise.
AMERICAN ORIENTAL BIOENGINEERING, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF INCOME AND COMPREHENSIVE INCOME (UNAUDITED) THREE MONTHS ENDED SIX MONTHS ENDED JUNE 30 JUNE 30 2010 2009 2010 2009 Revenues $77,296,212 $71,222,037 $131,045,980 $117,299,227 Cost of sales 37,455,860 29,594,923 62,968,907 47,255,261 GROSS PROFIT 39,840,352 41,627,114 68,077,073 70,043,966 Selling and marketing expenses 11,505,462 9,396,129 17,481,688 14,607,631 Advertising costs 9,217,247 7,779,936 15,965,717 13,347,293 Research and development costs 3,250,882 809,584 6,029,691 1,559,382 General and administrative expenses 5,158,104 4,026,425 9,924,590 8,417,126 Depreciation and amortization 1,622,989 1,623,556 3,219,947 3,256,142 Total operating expenses 30,754,684 23,635,630 52,621,633 41,187,574 INCOME FROM OPERATIONS 9,085,668 17,991,484 15,455,440 28,856,392 Equity in earnings (loss) from unconsolidated entities (170,799) (173,258) (53,326) 264,536 Interest expense, net 1,371,246 1,620,069 2,937,031 3,199,338 Other expenses, net 30,039 16,329 17,792 114,938 INCOME BEFORE INCOME TAXES 7,513,584 16,181,828 12,447,291 25,806,652 Income tax 2,395,850 3,735,558 4,211,780 6,205,322 NET INCOME 5,117,734 12,446,270 8,235,511 19,601,330 Net loss attributable to non-controlling interest 6,476 123,068 11,876 119,517 NET INCOME ATTRIBUTABLE TO CONTROLLING INTEREST 5,124,210 12,569,338 8,247,387 19,720,847 OTHER COMPREHENSIVE INCOME 1,843,654 21,945 1,936,503 513,282 COMPREHENSIVE INCOME $6,967,864 $12,591,283 $10,183,890 $20,234,129 EARNINGS PER COMMON SHARE Basic $0.07 $0.17 $0.11 $0.27 Diluted $0.07 $0.16 $0.11 $0.26 WEIGHTED AVERAGE SHARES OUTSTANDING Basic 74,743,986 74,582,920 74,680,327 74,560,809 Diluted 75,857,073 88,815,593 75,502,489 86,939,711 AMERICAN ORIENTAL BIOENGINEERING, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) JUNE 30, DECEMBER 31, 2010 2009 CURRENT ASSETS Cash and cash equivalents $96,433,832 $91,126,486 Restricted Cash 1,103,535 3,298,379 Accounts and notes receivable, net 66,767,659 57,504,454 Inventories, net 19,016,578 10,015,711 Advances to suppliers and prepaid expenses 5,937,021 13,901,180 Deferred tax assets 550,535 824,451 Other current assets 1,347,639 1,246,647 Total Current Assets 191,156,799 177,917,308 LONG-TERM ASSETS Property, plant and equipment, net 95,445,470 95,468,265 Land use rights, net 152,594,995 153,604,196 Other long term assets 7,967,784 7,909,086 Construction in progress 29,324,123 28,975,386 Other intangible assets, net 16,329,103 18,695,554 Goodwill 33,164,121 33,164,121 Investments in and advances to equity investments 57,441,048 57,325,887 Deferred tax assets 143,781 134,268 Unamortized financing costs 2,823,549 3,287,694 Total Long-Term Assets 395,233,974 398,564,457 TOTAL ASSETS $586,390,773 $576,481,765 LIABILITIES AND SHAREHOLDERS' EQUITY JUNE 30, DECEMBER 31, 2010 2009 CURRENT LIABILITIES Accounts payable $11,477,039 $7,497,143 Notes payable 1,103,535 3,392,575 Other payables and accrued expenses 16,935,522 22,320,757 Taxes payable 605,024 947,338 Short-term bank loans 8,959,257 10,384,368 Current portion of long-term bank loans 60,629 60,108 Other liabilities 4,842,631 2,199,280 Deferred tax liabilities 173,496 172,473 Total Current Liabilities 44,157,133 46,974,042 LONG-TERM LIABILITIES Long-term bank loans, net of current portion 710,598 743,957 Deferred tax liabilities 15,652,960 15,961,465 Unrecognized tax benefits 3,871,701 2,746,561 Convertible Notes 115,000,000 115,000,000 Total Long-Term Liabilities 135,235,259 134,451,983 TOTAL LIABILITIES 179,392,392 181,426,025 EQUITY SHAREHOLDERS' EQUITY Preferred stock, $0.001 par value; 2,000,000 shares authorized; 1,000,000 shares issued and outstanding at at June 30, 2010 and December 31, 2009, respectively 1,000 1,000 Common stock, $0.001 par value; 150,000,000 shares authorized; 78,580,138 and 78,321,419 shares issued and outstanding at June 30, 2010 and December 31, 2009,respectively. 78,580 78,321 Common stock to be issued 181,500 388,000 Prepaid forward repurchase contract (29,998,616) (29,998,616) Additional paid-in capital 201,806,789 199,829,921 Retained earnings (the restricted portion of retained earnings is $23,757,901 at June 30 and December 31, 2009.) 199,421,141 191,173,754 Accumulated other comprehensive income 34,986,727 33,050,224 Total Shareholders' Equity 406,477,121 394,522,604 Non-controlling Interest 521,260 533,136 TOTAL EQUITY 406,998,381 395,055,740 TOTAL LIABILITIES AND EQUITY $586,390,773 $576,481,765 For more information, please contact: ICR, LLC Christine Duan or Ashley Ammon Tel: +1-646-277-1200
agree... maybe the sales increase will be shown in the next 6-9 months with all the new drugs.. sometime cost will need to increase first before the revenue increase but it shouldn't lag too much.. so by end of year if sales not pickin up as fast they should cut the cost...
it's about time the consensus should be estimating 5-7 cents a share per quarter..
looks like the market already expecting the low EPS otherwise the stock will drop like 20-30% today
Nice to hear from you too Gary..
some things change while some/most others don't...
so I see you are still making good money from real estate.. very nice.. lot's of good deals around here too but not many people are buying..
Stan
Q22010: Net income of $5.8 million or $0.14 per diluted share, compared to $3.2 million or $0.7 per diluted share in 2009
----------
WEST PALM BEACH, Fla.--(BUSINESS WIRE)--Metropolitan Health Networks, Inc. (NYSE Amex:MDF), (“Metcare”) a leading provider of healthcare services in Florida, today announced the financial results for their second quarter ended June 30, 2010. Highlights include the following:
Net income of $5.8 million in the second quarter of 2010 or $0.14 per diluted share, compared to $3.2 million or $0.7 per diluted share in 2009’s second quarter;
a reduction in the medical expense ratio (“MER”) in the second quarter of 2010 to 83.8% from 89.8% in the second quarter of 2009;
net income of $12.9 million or $0.31 per diluted share for the six months ended June 30, 2010, compared to $7.2 million or $0.15 per diluted share for the same period in 2009;
a reduction in the MER to 82.8% for the first half of 2010 compared to 88.8% for the first half of 2009; and,
working capital of $40.9 million at June 30, 2010, up $13.2 million or 48% over December 31, 2009’s balance.
Second Quarter Financial Highlights:
The Company recognized revenue of $92.6 million for the second quarter of 2010 as compared to $87.1 million in the 2009 second quarter, a 6.3% increase. The Company’s medical expense ratio, or MER, was 83.8% in the second quarter of 2010 compared to 89.8% in the same quarter of 2009.
Operating income was $9.3 million in 2010 compared to $5.1 million in 2009. Net income for the 2010 second quarter was $5.8 million or $0.15 per share basic and $0.14 per diluted share as compared to $3.2 million or $0.07 per basic and diluted share for the same quarter last year. Weighted average common shares outstanding used to compute diluted earnings per share for the three month periods ended June 30, 2010 and 2009 were 41.2 million and 47.0 million, respectively.
Year to Date Financial Highlights:
For the six months ended June 30, 2010, the company’s revenue totaled $185.6 million compared to $177.5 million for the same period in the prior year, an increase of 4.6%. The Company’s MER, was 82.8% in the first six months of 2010 compared to 88.8% in the same period of 2009 and 88.5% for all of 2009.
Operating income was $20.5 million for the first six months of 2010 compared to $11.5 million for the same period in 2009. Net income was $ 12.9 million, or $0.33 per basic share and $0.31 per diluted share, compared to net income of $7.2 million, or $0.15 per basic and diluted share for the same period of 2009, an increase of 107% for diluted earnings per share. Weighted average common shares outstanding used to compute diluted earnings per share for the six month periods ended June 30, 2010 and 2009 were 41.1 million and 47.6 million, respectively.
Customer Information:
Medicare Advantage customers decreased slightly to 35,200 at June 30, 2010 as compared to 35,300 customers at June 30, 2009. Total customer months, the combined total customers for each month of the measurement period, for the first six months of 2010 increased by 0.3% to 212,200 in 2010 from 211,500 in 2009.
Balance Sheet Highlights:
Cash, cash equivalents and short-term investments at June 30, 2010 totaled $33.2 million compared to $33.8 million at December 31, 2009. Net working capital increased to $40.9 million at June 30, 2010 from $27.7 million at December 31, 2009. Included in working capital at June 30, 2010 is $10.7 million due from Humana. We expect to collect $8.5 million of this amount in August 2010.
Share Repurchase Program:
The Company’s Board of Directors has previously authorized the repurchase of up to 20 million shares of common stock. From the inception of the program through June 30, 2010 the Company has repurchased 13.7 million shares, and options exercisable to purchase 684,200 shares, at an average cost of $1.90 per share. Shares repurchased from January 1 through June 30, 2010 totaled approximately 1.7 million reducing total shares then outstanding to approximately 40.6 million. No shares were repurchased in the second quarter of 2010. Approximately 5.6 million shares remain available for purchase under the plan. The number of shares to be repurchased and the timing of the purchases will be influenced by a number of factors, including the then prevailing market price of the common stock of the Company, other perceived opportunities that may become available to the Company, and regulatory requirements.
Commenting on the results of the second quarter, Michael Earley, Chairman and Chief Executive Officer of Metropolitan Health Networks, Inc., stated, “2010 continues to be the best year in the company’s history, both in terms of financial results and in our positioning of the company to better serve our customers. In terms of financial performance, we, like most in our industry, are benefiting from lower utilization and cost trends in 2010. This, combined with changes in the benefits of the plans we service, has resulted in a lower medical expense ratio in 2010.”
Continuing, Earley noted, “The last two years were characterized by uncertainty with health care reform and in the financial markets. We took the opportunity to turn inward and focus on and invest in our operations and core business. The positive outcomes from these efforts are becoming clear. Our advances with the Patient Centered Medical Home model of care, the addition of medical and management staffing, and the implementation of new technology have produced benefits in 2010 and, we expect, will produce benefits in the future. Along with tangible financial performance, we are seeing measurable gains in customer satisfaction and employee engagement. A critical driver in our success has been our dedicated team of professionals, managers and staff that has accepted the challenge and embraced change, and we thank them for that. Today we are better positioned to address the needs of a growing senior population and better positioned to grow our business overall. The skills of providing and coordinating high quality care, of managing medical costs and risk, are more valuable than ever today. These skills, our scale, and a demographically explosive market, provide us ample opportunity for real growth in the future.”
that's the million dollar question john.. therea re so many opportunity out there with low pe.. some as low as 4 or 5.. last year or two years ago I had a few (ETLT and CXTI to name a few) where PE is 1-2 range.. and they both ran away.. pure fraud.. cooking the books.. what a waste.. just like Bush said.. fool me once shame on you, fool me twice shame on ...
for now I'm left with just a few chinese stocks (e.g. AOB, HQS, AWRCF etc) that I have bought a while back. not planning to add new chinese stocks until I don't see much opportunity inside US anymore (or till the chinese stocks numbers started to become more reliable, which I know is probably not going to happen).
Nonethelss, I'm still intrigued with NWD and how far it slide since the $1.6 and above. and tempted to pick up some but haven't seen any compelling reason yet.
and also looking into CKGT.OB again (I used to own this as well)
also looking into CSKI but haven't pull the trigger yet.
Stan
John
that's right.. $16 I forgot I thought it was $6.. I got some bought at the buy out price... but I have sold a lot before the buy out so bad luck for me , on the bright side I moved the money to some other stocks that has perform ok so I'm ok I guess.. but nonetheless, NTST was nice..
I will check out CAAH more. I briefly look into it and can't find much info on it. what's the story on it. thoughts on ASRG?
I once own some nwd.. the noodle company.. I can't beleive it's 8 cents now.. I used to own it at $1.5-$1.6 range. what's the story.. why are they dropping to 8 cents.. even insider selling at 12-13 cents last year for more than 1M shares.. why are they jumpping ship at 12 cents.. though so far the decision has been right. one guy sold 6M shares at 10 cents.. why would you wan tto buy when all insiders are dumping like crazy.. just an observation/question.. and whya re they still in AMEX and not in otcbb yet.. if they can be proftitable the stock will go up a lot but I'm not very optimistic after seeing so many insiders selling last year.. what's your angle on nwd..? tia.. I might buy some if the explanation make sense
YRCW i crazy any given day it an go up or down 20%
I wont be surprised if tomorrow it went down 20% again..
I might add one more time if it goes to like .25.. and then I will hold long term.. but it is indeed scary.. they might have to file bankruptcy or they might go to $1.. they might do 1:10 reverse split to make sure they stay in nasdaq
I missed the chance on DAN, most of my friend who own DA bought it at .60 and the rest is history.. (turn around play like YRCW though DAN doesn't dilute while YRCW dilute by issuing shares for debt, and without the interest payment they would have made $40M this quarter.)
Stan
hi John.. long time no see.. hope all is well.. I lost big money last year on ETLT and CXTI (or was it 2 years ago, time flies).. since then I'm doing ok I guess..
i have been following ltus as well.. but so far I put a lot of money in its competitor AOB (I keep loading up and last buy was 2.17) which will post earning next monday (probably another weak earning) I'm giving them time till q4 2010 (approx march 2011 report), then I'm bailin gout if EPS and stock price doesn't improve, in teh mean time I'm loading up the truck..
mgam is a buyout target.. hmm I will look into it..
F is solid though it's hard for me to invest in auto (but F has been going up really really nicely.. congrats).. miss big opportunity in DAN (I got a bunch of friends loading upa t .60-.80 , so now I tried to do that with YRCW and though I know it won't be the same ending since YRCW dilute a lot but I hope $1+ still reasonable and when they reverse 1 to 10 probably then the stock will be at $10)
I migh tpick up some LTUS soon..
thoughts on CSKI?
also thinking on CKGT.OB
MDF is posting on wednesday, finally after more than 6 years, it becomes a tenbagger for me.. glad that I hang on to it.. 6 years is long time but time flies.. I wonder what happen to our NTST now (which was a tenbagger when it is $12-$14 range for us too before they drop again and get bought out at around $6 if I'm not mistaken?
Stan
PS;
here's a list that seeking alpha like (AOB is not in the list but I'me ncouraged as AOB board is also not many people there so no bashers or shorts around either)
Lotus Pharmaceuticals (LTUS.OB)
Renhuang Pharmaceuticals (RHGP.OB)
Weikang Bio-Tech (WKBT.OB)
Biostar Pharmaceuticals (BSPM)
China Biologic Products (CBPO)
China Jo-Jo Drugstores (CJJD)
China Kangtai Cactus (CKGT.OB)
Huifeng Bio-Pharma (HFGB.OB)
Nutrastar Int. (NUIN.OB)
fbi long time no see/chat..
why you took all your money from stock market.. are you saying teh amrekt is overheating now.. it is very volatile but shouldn't volatility your best friend (as a trader)
that's right you like football. college? or pro as well> you thin kbrett favre is coming back? will tebow make a difference in his first year ? what about NFC east.. mcnabb going to redskin kolb and vick in eagles.. cowboys looking good too.. and giants not a bad team too.. that's a strong/scary division..
you playin gpoker too? hold'em? cash games? tournament? online? fun? been winning?
YRCW tomorrow morening will post earning
stock at .40 and jan 2011 $1 call option is at 10-11 cents.. that is like 25% return in six months if you issue the call option..
I bought my last batch (my largest one too) at .15 recently and I should have issued the call option todya as I don't think the stock will go to $1+ anytime soon, but I was too greedy and just want to ride the stock long term (for multi bagger)
Hope you have a great summer so far (looks like it with all the football bets that youare making)
Stan
PS: do you parlay any of your footbal bets. (multiple game parlay)
What's holding AWRCF back are (IMO):
1. Need national listing
2. Restoring/More credibility from management (past history of bad management, and some fraud, but I think they fired all those people who are involved)
3. Take SEC listing and reporting requirement more seriously (in the past they have skipped reporting earning and report only twice or less in a year)
4. Institutional support (MSD is the only big one and they also has sold some of their shares not too long ago)
5. Need more consistency. Revenue fluctuation is big (annual sales can go up or down a couple hundred million of dollar from one year to another, and consequently net income swing back and forth from profit and loss)
6. Just the fact this is international/asian/chinese stock (emerging market risk)
7. Price is so low that people are wondering if this is too good to be true.
8. The company structure doesn't seem to make sense to me (unless they want to take benefit of off balance sheet stuff which I don't think is a good idea to begin with), i.e. PEWC and APWC/AWRCF. why not PEWC and APWC merge together instead of spun off and list the APWC only on OTCBB. AWRCF should merge back with PEWC and list together. (This one is just my personal thought as well)
I'm long and strong but on this stock, it can still go either way (it can go back to $1 and you won't hear from the company for a long time. it has happened before and can happen again, or it can go to $6 and above if they manage to address all the items above)
Best of luck to us longs..
Stan
any of you playing YRCW.. I'm long on it but the volatility should interest you guys.. i.e. fbiciaman who seems to like to swing trade on volatile stocks (and with big money too)..
the past week or so YRCW has been up (or down) 10-20% everyday..
New contracts.. from elite companies.. one of them is Marubeni from Japan...
TAIPEI, July 28 /PRNewswire-Asia-FirstCall/ -- Asia Pacific Wire & Cable Corporation Limited (OTC Bulletin Board:AWRCF.ob - News) ("APWC" or the "Company"), a leading manufacturer of wire and cable products for the telecommunications and electric-power industries in selected Asia-Pacific markets, today announced that one of its Thai subsidiaries, Siam Fiber Optics, Co, Ltd. ("SFO"), has signed several major contracts with local companies and state-owned telecommunication companies for a total value of Baht 592 million (approximately $18.4 million). These contracts include:
-- A THB 185 million ($5.7 million) contract with Marubeni Thailand Co., Ltd. to deliver 5,650 km of fiber-optic cable over a seven-month period through October 2010; -- A THB 121 million ($3.8 million) contract to deliver 2,794 km of fiber-optic cable to TOT Public Company Limited, a state-owned telecommunications company, which commenced in May 2010 and would run for four months; and -- Two contracts from Thai Transmission Industry Co., Ltd. to provide 4,130 km ADSS & 4,324 km Dropwires of fiber-optic cables in an effort to link the telecommunication network for all the domestic universities in Thailand totaling THB 258 million (approximately $8.0 million) over approximately 14 months, the first of which commenced in January 2010.
Siam Fiber Optics Co., Ltd. is 60% owned by Charoong Thai Wire and Cable Co., the latter is 51% directly or indirectly owned by APWC. The other three non-controlling interest parties own rest of the 40% of Siam Fiber Optics Co., Ltd.
Asia Pacific Wire and Cable Corporation is pleased by the strong demand for the telecommunications products in Thailand and optimistic about experiencing a continued recovery in our business. These contracts represent a healthy pipeline and stable growth in our telecommunications-cable business. The Company expects to see continued strong demand for our wire and cable alongside the expansion of telecommunications and electrical infrastructure in the growing Asia-Pacific region
Nice Q2 earning, nice cash balance, nice dividend, nice cost control, nice/tighter guidance, Congrats USMO management!
========================
SPRINGFIELD, Va.--(BUSINESS WIRE)--USA Mobility, Inc. (Nasdaq: USMO - News), a leading provider of wireless messaging and communications services, today announced operating results for the second quarter ended June 30, 2010.
In addition, the Company’s Board of Directors declared a regular quarterly cash distribution of $0.25 per share, payable on September 10, 2010 to stockholders of record on August 19, 2010. Of the $0.25 cash distribution, the Company expects $0.23 will be a return of capital and $0.02 will be a dividend distribution.
Total revenue for the second quarter was $59.1 million, compared to $62.8 million in the first quarter of 2010 and $75.1 million in the year-earlier quarter. Second quarter EBITDA (earnings before interest, taxes, depreciation, amortization and accretion) totaled $20.4 million, compared to $22.0 million in the first quarter and $24.0 million in the second quarter of 2009.
Net income for the second quarter was $13.1 million, or $0.58 per fully diluted share, compared to $8.9 million, or $0.39 per fully diluted share, in the first quarter, and $44.7 million, or $1.93 per fully diluted share, in the year-earlier quarter. The second quarter of 2009 net income included a one-time income tax benefit of $37.0 million due to the settlement of uncertain tax positions and tax refund claims and a litigation settlement expense of $4.0 million. Excluding those two items, net income in the year-earlier quarter would have been $10.1 million, or $0.43 per fully diluted share. In the second quarter of 2010, the Company reassessed the expected level of the Company’s 2010 taxable income, which allowed the Company to reduce the deferred tax asset valuation allowance by $4.7 million with a corresponding reduction in income tax expense. Absent the reduction in income tax expense, net income would have been $8.4 million or $0.37 per fully diluted share.
Second quarter results included:
Net unit loss was 72,000 in the second quarter, compared to 83,000 in the prior quarter and 158,000 in the second quarter of 2009. Units in service totaled 2,027,000 at June 30, 2010, compared to 2,449,000 a year earlier.
The quarterly rate of subscriber loss improved to 3.5 percent, compared to 3.8 percent in the first quarter and 6.0 percent in the second quarter of 2009. The annual rate of subscriber erosion also improved to 17.2 percent in the second quarter from 19.5 percent in the first quarter and 22.9 percent in the year-earlier quarter.
Total paging ARPU (average revenue per unit) was $8.87 in the second quarter, compared to $9.00 in the first quarter and $8.96 in the year-earlier quarter.
The quarterly rate of revenue erosion was 5.8 percent, compared to 4.0 percent in the prior quarter and 5.7 percent in the second quarter of 2009. The annual rate of revenue erosion was 21.3 percent, compared to 21.2 percent in the first quarter and 18.4 percent in the year-earlier quarter.
Operating expenses (excluding depreciation, amortization and accretion) totaled $38.7 million in the second quarter, a reduction of $12.5 million, or 24.4 percent, from $51.2 million in the second quarter of 2009. Operating expenses declined 5.3 percent from the prior quarter.
EBITDA margin (or EBITDA as a percentage of revenue) was 34.6 percent, compared to 31.9 percent in the second quarter of 2009.
Capital expenses were $0.6 million in the quarter, compared to $4.4 million in the year-earlier quarter, due to fewer paging device purchases.
The Company repurchased 176,839 shares of common stock during the quarter under its buy back program, and approximately $18.1 million remains available for purchases under the currently approved plan.
The Company’s cash balance at June 30, 2010 was $129.1 million.
Vincent D. Kelly, president and chief executive officer, said: “USA Mobility reported another quarter of solid operating results, meeting or exceeding the majority of our key performance objectives. We were particularly pleased to see continued improvement in the pace of subscriber erosion, which slowed for the third consecutive quarter. At the same time, revenue, ARPU, and operating margins remained at high levels while our expense reduction efforts continued on track, all consistent with the financial guidance we provided earlier this year. In addition, we again generated sufficient cash flow during the quarter to return significant capital to stockholders in the form of cash distributions and share repurchases.”
Thomas L. Schilling, chief operating officer and chief financial officer, said the Company continued to pursue various cost reduction initiatives during the quarter. “Operating expenses (excluding depreciation, amortization and accretion) decreased 5.3 percent from the first quarter and 24.4 percent over the past 12 months,” Schilling noted, “including significant reductions in payroll expense and site rent expense. Operating expense as a percentage of revenue was 65.4 percent in the quarter, compared to 68.1 percent in the year-earlier quarter, with the lower expenses contributing to an EBITDA margin of 34.6 percent versus 31.9 percent in the same quarter of 2009.”
Based on current trends, the Company is revising its financial guidance for 2010. Revenues are now expected to be between $230 million to $235 million, operating expenses (excluding depreciation, amortization and accretion) between $156 million to $159 million, and capital expenses between $7 million to $9 million.
all right.. thanks.. I've been buying at under $2 for many years (and never sold even when it goes to $6 last time) and wonder if I should add more at these levels..
fox.. so you found AOB earlier before I did.. I didn't find/buy until the first dip from $5 to $1.3. that's when I started buying and the PE was about 8 that time.. their earning per share was .15.. but they have much less shares back then. the additional shares added since 2004 is also the reason why EPS has been slowing down (they did increase from .15 and that's why the stock is up to $15 and the PE was over 30 at that time)
so are you long on this stock? what is your target? or what do you think AWRCF should be worth..
got it eastunder... we're here to be the living proof that long term investing (and value investing, or GARP investing) isn't dead.. which I know is a tough task to do..
I know trading and market timing has been the new trend since the 2008 collapse..
GL to you too.. to us..
Go AOB...
same here.. loaded up a lot of AOBO.OB at $1.3 back then in 2004 and 2005... the good old days...
did you sell some along the way.. I didn't sell much but I did sell some as high as $8.65.. but nothing above $10.. Tony seems to sell at the right time... (he sold only 1M shares though)
thanks.. and I hope you are not being sarcastic ;)
lol.. classic trader vs long term investor (who is still building their position)
hmm... on second thought going $4 next week is fine by me too.. I had a lot of shares already, and sometime greed is not good I guess..
best of luck to both of us (and all other AOB longs. I assume you are long on AOB by your comment)
yeah.. and I'm still adding..
it will be nice to keep it under $3 till the end of the year.. but if it is still under $3 next year, then it's probably bigger trouble ahead for them...
long and strong..